Home/Filings/4/0002072013-25-000006
4//SEC Filing

Power Luke Thomas 4

Accession 0002072013-25-000006

CIK 0002019410other

Filed

Dec 11, 7:00 PM ET

Accepted

Dec 12, 7:39 PM ET

Size

14.4 KB

Accession

0002072013-25-000006

Insider Transaction Report

Form 4
Period: 2025-12-11
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-11$2.44/sh+24,750$60,390124,321 total
  • Exercise/Conversion

    Common Stock

    2025-12-11$2.44/sh+37,500$91,500161,821 total
  • Sale

    Common Stock

    2025-12-11$26.56/sh60,850$1,616,444100,971 total
  • Sale

    Common Stock

    2025-12-11$27.16/sh1,400$38,01899,571 total
  • Exercise/Conversion

    Stock Option

    2025-12-1124,7500 total
    Exercise: $2.44Exp: 2027-05-30Common Stock (24,750 underlying)
  • Exercise/Conversion

    Stock Option

    2025-12-1137,5000 total
    Exercise: $2.44Exp: 2028-11-14Common Stock (37,500 underlying)
Footnotes (4)
  • [F1]The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.11 to $27.07, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.20, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The stock option is fully vested and exercisable.

Issuer

Caris Life Sciences, Inc.

CIK 0002019410

Entity typeother

Related Parties

1
  • filerCIK 0002072013

Filing Metadata

Form type
4
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 7:39 PM ET
Size
14.4 KB